Watch for the fairness opinion on Alchemy (due before Record Date) which could trigger price renegotiation or termination of both offers. CFIUS review is a key condition; a mandatory 30-day declaration will be filed. The final offer price depends on liabilities and share count at the Record Date.
How the stock moved after the report
BULLISH VIEWSTOCK AT ENTRY AT T+5- T+0 · Nov 3 $0.0300entry
- T+1 · 6d ago +3.33%α +1.58% · $0.0310
- T+5 · 11h ago 0.00%α +0.65% · $0.0300
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
Executive Summary
The CVAT board unanimously recommends shareholders accept BrightFlixx's cash tender offer at an estimated $0.0975-$0.1029 per share, citing the company's lack of revenue after its 2024 patent sale to Desmet, constrained cash flow, and inability to commercialize new technologies without substantial capital. The Alchemy board takes a neutral position pending a fairness opinion. The offers are cross-conditioned and subject to CFIUS clearance and a 90% minimum tender condition.
Key Financial Metrics
Key Facts
- CVAT board unanimously recommends shareholders accept the BrightFlixx cash tender offer at an estimated $0.0975-$0.1029 per share
- Alchemy board takes neutral position on its tender offer pending a fairness opinion
- Tender offer price formula: $35M less liabilities divided by shares outstanding at Record Date (Dec 24, 2026)
- Offers are cross-conditioned: each requires the other to close; CFIUS clearance and 90% minimum tender are conditions
- No golden parachute compensation; no employment agreements with officers; no D&O insurance maintained
- CEO Neil Voloshin (5.5% owner) intends to tender all his CVAT shares; independent directors hold only warrants
- Company has minimal revenue after October 2024 patent assignment to Desmet ended its primary revenue stream
- Company issued a $100,000 convertible note on Oct 29, 2026 for general corporate purposes
Financial Impact
Estimated offer price $0.0975-$0.1029 per share vs. recent trading price of $0.0303, representing ~300% premium; aggregate deal value $35M less liabilities
Risk Factors
- CFIUS review could block or delay the transaction
- Fairness opinion on Alchemy may trigger price renegotiation or termination of both cross-conditioned offers
- 90% minimum tender condition may not be met
- Company's financial condition is weak with minimal revenue and constrained cash flow
- Offer price is variable and depends on liabilities and share count at Record Date
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 14D-9 Filing (Primary) | 0001683168-26-008260 |
| Document: 0001683168-26-008260-index-headers.html | 0001683168-26-008260 |
| Document: 0001683168-26-008260-index.html | 0001683168-26-008260 |
| Document: 0001683168-26-008260.txt | 0001683168-26-008260 |
Track record
5 reports on CVAT
1 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +20.00% at T+20 after the Sep 28, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 3, 20267d ago SC 14D-9 Bullish 7/10 Viewing Entry $0.0300 to $0.0310 Now $0.0310 +3.33% ▲ +3.33% +1.58% vs SPY
- Oct 21, 202620d ago SC TO-T Bullish 7/10 Entry $0.0400 to $0.0400 Now $0.0310 −22.50% · 0.00% +1.18% vs SPY
- Oct 13, 202628d ago 8-K Bullish 7/10 Entry $0.0300 to $0.0300 Now $0.0310 +3.33% · 0.00% +1.08% vs SPY
- Sep 28, 20266w ago NT 10-K Bearish 6/10 Entry $0.0400 to $0.0400 Now $0.0310 +22.50% · 0.00% −0.18% vs SPY
- Aug 19, 202611w ago 8-K Bullish 7/10 Entry $0.0400 to $0.0402 Now $0.0310 −22.50% ▲ +0.50% +1.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers